CN1298719C - 嘌呤衍生物、其制备方法和含有它们的药物组合物 - Google Patents

嘌呤衍生物、其制备方法和含有它们的药物组合物 Download PDF

Info

Publication number
CN1298719C
CN1298719C CNB008106509A CN00810650A CN1298719C CN 1298719 C CN1298719 C CN 1298719C CN B008106509 A CNB008106509 A CN B008106509A CN 00810650 A CN00810650 A CN 00810650A CN 1298719 C CN1298719 C CN 1298719C
Authority
CN
China
Prior art keywords
product
formula
alkyl
amino
purine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008106509A
Other languages
English (en)
Chinese (zh)
Other versions
CN1361780A (zh
Inventor
J·－L·海斯莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CN1361780A publication Critical patent/CN1361780A/zh
Application granted granted Critical
Publication of CN1298719C publication Critical patent/CN1298719C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB008106509A 1999-05-21 2000-05-18 嘌呤衍生物、其制备方法和含有它们的药物组合物 Expired - Fee Related CN1298719C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906456A FR2793794B1 (fr) 1999-05-21 1999-05-21 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
FR99/06456 1999-05-21

Publications (2)

Publication Number Publication Date
CN1361780A CN1361780A (zh) 2002-07-31
CN1298719C true CN1298719C (zh) 2007-02-07

Family

ID=9545846

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008106509A Expired - Fee Related CN1298719C (zh) 1999-05-21 2000-05-18 嘌呤衍生物、其制备方法和含有它们的药物组合物

Country Status (33)

Country Link
US (2) US7122669B1 (https=)
EP (1) EP1183256B1 (https=)
JP (1) JP2003500407A (https=)
KR (1) KR100707895B1 (https=)
CN (1) CN1298719C (https=)
AP (1) AP1477A (https=)
AR (1) AR035317A1 (https=)
AT (1) ATE370951T1 (https=)
AU (1) AU4764500A (https=)
BR (1) BR0011282A (https=)
CA (1) CA2374714A1 (https=)
CZ (1) CZ20014163A3 (https=)
DE (1) DE60036102T2 (https=)
DK (1) DK1183256T3 (https=)
DZ (1) DZ3166A1 (https=)
EA (1) EA005072B1 (https=)
ES (1) ES2290033T3 (https=)
FR (1) FR2793794B1 (https=)
HU (1) HUP0201649A3 (https=)
IL (1) IL146441A0 (https=)
MA (1) MA26791A1 (https=)
MX (1) MXPA01011834A (https=)
NO (1) NO20015659L (https=)
NZ (1) NZ515556A (https=)
PL (1) PL352293A1 (https=)
PT (1) PT1183256E (https=)
SK (1) SK16722001A3 (https=)
TR (1) TR200103349T2 (https=)
TW (1) TWI284130B (https=)
UA (1) UA68441C2 (https=)
WO (1) WO2000071543A1 (https=)
YU (1) YU86601A (https=)
ZA (1) ZA200109602B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
AU3938802A (en) * 2000-10-31 2002-06-03 Aventis Pharma Inc Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US7951592B2 (en) * 2003-11-10 2011-05-31 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
CA2563123A1 (en) * 2004-04-02 2005-10-20 Adenosine Therapeutics, Llc Selective antagonists of a2a adenosine receptors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
CN114149432B (zh) * 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂
CZ308029B6 (cs) * 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
JP2026500305A (ja) 2022-12-16 2026-01-06 アストラゼネカ・アクチエボラーグ ２，６，９三置換プリン

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016452A1 (en) * 1995-11-01 1997-05-09 Novartis Ag Purine derivatives and processes for their preparation
WO1997020842A1 (fr) * 1995-12-01 1997-06-12 Centre National De La Recherche Scientifique (C.N.R.S.) Nouveaux derives de purine possedant notamment des proprietes anti-proliferatives et leurs applications biologiques
WO1998005335A1 (en) * 1996-08-02 1998-02-12 Cv Therapeutics, Inc. PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a)
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
EP0841810B1 (en) * 1991-12-05 2000-06-21 Texas Instruments Incorporated Method to improve a video signal
CA2084222C (en) * 1991-12-06 2004-04-06 David R. Borcherding Novel trans cyclopentanyl purine analogs useful as immunosuppressants
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016452A1 (en) * 1995-11-01 1997-05-09 Novartis Ag Purine derivatives and processes for their preparation
WO1997020842A1 (fr) * 1995-12-01 1997-06-12 Centre National De La Recherche Scientifique (C.N.R.S.) Nouveaux derives de purine possedant notamment des proprietes anti-proliferatives et leurs applications biologiques
WO1998005335A1 (en) * 1996-08-02 1998-02-12 Cv Therapeutics, Inc. PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a)
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases

Also Published As

Publication number Publication date
SK16722001A3 (sk) 2003-01-09
PT1183256E (pt) 2007-11-13
JP2003500407A (ja) 2003-01-07
MXPA01011834A (es) 2002-04-17
EP1183256A1 (fr) 2002-03-06
KR20010113975A (ko) 2001-12-28
DE60036102D1 (de) 2007-10-04
IL146441A0 (en) 2002-07-25
CN1361780A (zh) 2002-07-31
FR2793794A1 (fr) 2000-11-24
ATE370951T1 (de) 2007-09-15
NZ515556A (en) 2003-08-29
CA2374714A1 (fr) 2000-11-30
DE60036102T2 (de) 2008-05-15
YU86601A (sh) 2005-07-19
US7122669B1 (en) 2006-10-17
EA005072B1 (ru) 2004-10-28
BR0011282A (pt) 2002-02-26
DZ3166A1 (fr) 2000-11-30
ES2290033T3 (es) 2008-02-16
NO20015659D0 (no) 2001-11-20
CZ20014163A3 (cs) 2002-10-16
AP1477A (en) 2005-10-19
US7208598B2 (en) 2007-04-24
US20050187228A1 (en) 2005-08-25
AU4764500A (en) 2000-12-12
AR035317A1 (es) 2004-05-12
EP1183256B1 (fr) 2007-08-22
HUP0201649A2 (en) 2002-08-28
WO2000071543A1 (fr) 2000-11-30
EA200101224A1 (ru) 2002-10-31
TR200103349T2 (tr) 2002-05-21
AP2001002355A0 (en) 2001-12-31
KR100707895B1 (ko) 2007-04-17
TWI284130B (en) 2007-07-21
MA26791A1 (fr) 2004-12-20
ZA200109602B (en) 2003-01-29
UA68441C2 (en) 2004-08-16
HUP0201649A3 (en) 2003-01-28
PL352293A1 (en) 2003-08-11
FR2793794B1 (fr) 2001-07-27
DK1183256T3 (da) 2007-12-03
NO20015659L (no) 2002-01-18

Similar Documents

Publication Publication Date Title
CN1298719C (zh) 嘌呤衍生物、其制备方法和含有它们的药物组合物
CN1267431C (zh) 取代的喹唑啉衍生物及其在制备作为抑制剂的药物中的用途
CN100351239C (zh) 嘧啶衍生物及其用作cb2调节剂的用途
CN1432015A (zh) 可用作细胞增殖抑制剂的被1,1－二氧代异噻唑烷取代的吲唑
CN1950343A (zh) 胺系碱性化合物及其用途
CN1070173C (zh) 用作药物的苯甲酰基胍衍生物
CN1193276A (zh) 氧化－角鲨烯环化酶抑制剂的降低血中胆甾醇的应用
CN1157617A (zh) 杂双环衍生物
CN1684957A (zh) 作为组蛋白脱乙酰酶抑制剂的取代的噻吩基－异羟肟酸
CN1553899A (zh) 抑制肝细胞生长因子受体自磷酸化的喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
CN1378537A (zh) 嘧啶衍生物
CN1038586C (zh) 吡嗪衍生物的制备方法
CN1248259A (zh) 稠合的哒嗪衍生物、其生产方法和用途
CN1328550A (zh) 作为前列腺素e2激动剂或拮抗剂的噁唑化合物
CN1089947A (zh) 新的杂环化合物
CN1305454A (zh) 作为cgmp－磷酸二酯酶抑制剂的邻氨基苯甲酸衍生物
CN1215055C (zh) 芳基磺酰氨基取代的异羟肟酸衍生物
CN1329614A (zh) 稠合的哒嗪衍生物、它们的制备方法和用途
CN1764648A (zh) 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
CN1656086A (zh) 苯并呋喃衍生物
CN1084846A (zh) 乙醇胺衍生物
CN1030450C (zh) 镇痛羧酸酰胺衍生物的制备方法
CN86102349A (zh) 制备n-[(4-哌啶基)烷基]取代的双环稠合的唑与噻唑胺之方法
CN1489582A (zh) 二氢化萘衍生物及包含该衍生物作为活性成分的药物
CN1100415A (zh) 制备咪唑的硫化衍生物的新方法和所得到的新型中间体

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070207